Astellas Pharma Inc. and Ocata Therapeutics, Inc., a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, …
Big Data, Combo Drugs, Implants Will Be Focus of AAO 2015
Research from the national IRIS Registry will be presented at the American Academy of Ophthalmology meeting, along with the latest on combination options for macular degeneration and diabetic edema. Medscape Medical News
Uncategorized
SMILE shows stable results after 3 years
Small incision lenticule extraction may produce stable refractive and visual outcomes out to 3 years in patients with high myopia, according to a study.The study determined the long-term outcomes of small incision lenticule extraction (SMILE) in 87 pat…
Ocular Therapeutix™ Expands Its Board of Directors with the Election of Industry Leader W. James O’Shea
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today that W. James O’Shea, former President and Chief Operating Officer of Sepracor Inc., has been elected to Ocular’s Board of Directors. “We are very pleased to announce that Jim is joining our Board. With a more than 40-year tenure in the biopharma industry, Jim has ext
American Academy of Ophthalmology (AAO) 2015 Annual Meeting
Read clinically focused news coverage of key developments from AAO 2015. Medscape Ophthalmology
Uncategorized
NICE raccomanda l’utilizzo di IKERVIS® in Inghilterra per il trattamento dei pazienti adulti affetti da secchezza oculare con cheratite severa
OSAKA, Giappone–(BUSINESS WIRE)–Santen Pharmaceutical Co., Ltd. (di seguito Santen) ha annunciato oggi che il National Institute for Health and Care Excellence (NICE) ha emesso una Final Appraisal Determination (FAD) positiva, raccomandando in Inghilterra l’utilizzo di IKERVIS® Santen (ciclosporina 1 mg/mL collirio, emulsione, in confezioni monodose) per il trattamento della cheratite severa in pazienti adulti affetti da secchezza oculare, non migliorata malgrado il trattamento con sostituti